Chinese Scientists Use CRISPR Technology to Repair Pathogenic Mutations in Viable Human Embryos

The study marks milestone progress over previous attempts to remodel the human embryos DNA. It work well in embryos created by a standard in-vitro fertilization technique called "germline editing". The research is published last week in the journal Molecular Therapy.

Chinese scientists corrected a mutation that causes Marfan syndrome, an incurable connective tissue disorder that affects about 1 in 5,000 people. A single letter mistake in the gene for FBN1, which codes for the fibrillin protein, can cause ripple effect problems-from loose joints to weak vision to life-threatening heart damage. The team of researchers from Shanghai Tech University and Guangzhou Medical University used an IVF technique to make viable human embryos. Then they injected the embryos with a CRIPR construct known as a base editor, which swaps out a single DNA nucleotide for another-n this case, removing an "A" and replacing it with a "G".

Sequencing revealed that all 18 embryos had been edited, with 16 of the embryos corrected version of the FBN1 gene. In two of the embryos, additional unwanted edits had also taken place.

GenScript Offers Synthetic sgRNAs NEW
- For Achieving THE BEST Genome Editing Efficiency in Any Cell!

GenScript synthesizes both unmodified and modified sgRNAs for targeted genome editing. Modified sgRNAs with 2’-O-methyl and phosphorothioate modifications at the first three 5’ and 3’ terminal residues are recommended for better stability and editing efficiency.

Number 1

4 nmol guaranteed delivery quantity from just $259

Number 2

ISO9001 certificated, comprehensive quality assurance:

Number 3

ESI-MS guaranteeing mass variation <1‰

Number 4

RNase-free HPLC results guaranteeing more than 90% purity

Number 5

Shipped in as short as 8 business days

Number 6

Fully customizable, 97-103 nt, allowing for greater flexibility in sgRNA design

Subscribe to Receive Updates
& Promotions From GenScript

* We'll never share your email address with a third-party.

Latest News & Blogs

Find More CRISPR News
feedback

Do you like the current new website?

Hate

Dislike

Neutral

Like

Love

*